Tags: Drug.
Blosozumab binds SOST a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.Blosozumab was developed by Eli Lilly and Company.
Loading...
This page contains content from the copyrighted Wikipedia article "Blosozumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.